Healthcare >> Analyst Interviews >> March 26, 2001

Analyst Interview: Outlook For Genomics Companies

Charles C. Duncan joined JMP Securities LLC in November 2002 as a Managing Director and Senior Research Analyst covering biotechnology. Prior to joining JMP, he had served as Director of U.S. Equities and as a biotechnology analyst at Dresdner Kleinwort Wasserstein Securities from July 2001. He previously spent a year at Prudential Vector Healthcare Group and its predecessor, Vector Securities International, as a Senior Vice President following biotechnology and genomics. He began his equity research careerat Tucker Anthony Cleary Gull, where he covered drug development and therapeutics from March 1997 through May 2000. He is a member of the Association for Investment Management Research, the Denver Society of Security Analysts, the American Association for the Advancement of Science and the Society of Neuroscience. He received a PhD in Pharmaceutical sciences from the University of Colorado and a BS degree in Zoology and Molecular Biology from the University of Wisconsin, Madison. Profile
TWST: Will you begin by telling us about the approach that youve taken to the science of genomics and to evaluating the investment opportunities associated with the sector?

Dr. Duncan: